The first two centres have been activated for the SPRINT clinical trial – EORTC
EORTC shared a post on LinkedIn:
“We are excited to announce that the first two centres have been activated for the SPRINT clinical trial, the first pan-European Trial within Cohorts (TwiCs), leveraging real-world data from the E2RADIatE OligoCare cohort to evaluate treatment strategies for patients with oligometastatic breast, prostate, lung, and colorectal cancers.
The study aims to determine whether a single fraction of stereotactic body radiotherapy (SBRT) can be as effective as multi-fraction SBRT—potentially reducing treatment burden while improving patient experience and quality of life.
With the support of the Rising Tide Group, SPRINT is set to provide valuable insights that could shape the future of radiotherapy for oligometastatic disease.
Find out more.
The E²RADIatE platform is supported by Walgreens Boots Alliance.“
More Posts featuring EORTC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023